Ritter Pharmaceuticals Hosts Conference Call on August 7, 2019 to Highlight Recent Lactose Intolerance Market Research Findings
July 31, 2019 09:00 ET
|
Ritter Pharmaceuticals, Inc.
Daniel P. Lundberg, Consultant to Ritter Pharmaceuticals and former Senior VP of Marketing at Salix Pharmaceuticals to address market opportunity for Phase 3, lactose intolerance drug candidate RP-G28...
Ritter Pharmaceuticals Announces Last Patient Last Visit in its Phase 3 “Liberatus” Clinical Trial of RP-G28 for Lactose Intolerance
July 02, 2019 09:00 ET
|
Ritter Pharmaceuticals, Inc.
Top-line Data Readout Remains on Track for early Q4 2019 LOS ANGELES, July 02, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a...
Ritter Pharmaceuticals Completes Dosing of Last Patient in Pivotal 557-Subject Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance
May 07, 2019 09:15 ET
|
Ritter Pharmaceuticals, Inc.
Top-line Data Readout on Target for early Q4 2019 LOS ANGELES, May 07, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a...
Ritter Pharmaceuticals Reports Year End 2018 Financial Results and Provides Business Update
March 29, 2019 09:00 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, March 29, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of therapeutic products that modulate the gut...
Ritter Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance
March 05, 2019 08:30 ET
|
Ritter Pharmaceuticals, Inc.
Top-line Data Readout Expected in early Q4 2019 LOS ANGELES, March 05, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a...
Dr. William Chey Highlights Unmet Medical Need of Lactose Intolerance and Potential for Phase 3 Drug Candidate RP-G28 in Expert Call Hosted by Ritter Pharmaceuticals
February 28, 2019 08:30 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate...
Ritter Pharmaceuticals to Host Expert Call with Dr. William Chey on February 20, 2019
February 12, 2019 08:30 ET
|
Ritter Pharmaceuticals, Inc.
Leading Gastrointestinal Disease Expert to Address Unmet Medical Need in Lactose Intolerance and the Potential of Phase 3 Drug Candidate RP-G28 LOS ANGELES, Feb. 12, 2019 (GLOBE NEWSWIRE) -- ...
Ritter Pharmaceuticals Reaches Halfway Mark for Enrollment in Pivotal Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance
December 04, 2018 08:30 ET
|
Ritter Pharmaceuticals, Inc.
Full Enrollment on Target for Q2 2019 with Data Readout Expected in the Second Half of 2019 LOS ANGELES, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter...
Ritter Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2018 and Recent Progress
November 09, 2018 07:00 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the...
Ritter Pharmaceuticals to Present at 20th Annual HC Wainwright Global Investment Conference on September 5, 2018
August 28, 2018 13:31 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the...